Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Alkermes Broaden Inhaled Insulin Manufacturing Agreement

This article was originally published in The Pink Sheet Daily

Executive Summary

The update ensures adequate supplies of insulin powder “if and when” the AIR inhaled insulin system is launched, Lilly told “The Pink Sheet” DAILY.

You may also be interested in...



Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade

Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.

Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade

Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.

Diabetes Drug Spend Could Rise 70 Percent By 2009, Medco Predicts

Driven by rising obesity rates, spending on diabetes therapies rose 14.5 percent from 2005 to 2006, firm’s annual Drug Trend Report states.

Related Content

Topics

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel